Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Blackrock Silver Drills 5.03 Metres of 750 g/t AgEq and Reports Multiple Thick Mineralized Zones in First Assays from Eastern Expansion Drill Program at Tonopah West
